

Date: 13th November, 2019

To,

EMERGE PLATFORM OF NSE
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

Subject: Outcome of Board Meeting held on Wednesday, 13th November, 2019.
SYMBOL: AJOONI


Dear Sir/Madam,

Pursuant to the provisions of Regulations 30(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors in their meeting held on Wednesday, 13th November, 2019 at 4:00 P.M. and concluded at 4:45 p.m.:

1. Considered and Approved and taken on records the Unaudited Financial Results along with Limited Review Report for the Half Year ended on September 30, 2019 . You are requested to take the same on record and acknowledge receipt.

Thanking You,
Yours Truly,

For Ajooni Biotech Limited



Jasjot Singh
Managing Director
DIN: 01937631



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on the Half Yearly and Year to Date Unaudited
Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

The Board of Directors,
Ajooni Biotech Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Ajooni Biotech Limited ("the Company") for the Half Year ended September 30, 2019 and year to date from April 01, 2019 to September 30, 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors in their meeting held on November 13, 2019, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133, of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



House No. 1122, Sector 71, Mohali
Mobile : 096460-27023, 098120-27023

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Company
Chartered Accountants

FRN: 019187R



CA Harjeet Singh

FCA

M.No 095466

UDIN: 19095466AAAAFJ4383

Place: Mohali

Date: 13th Day of November, 2019

AJOONI BIOTECH LIMITED
CIN : U85190PB2010PLCO40162

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30.09.2019 (RS. IN LAKHS)

	PARTICULARS	Half Yearly			Yearly	
		30.09.2019 (Unaudited)	31.03.2019 (Unaudited)	30.09.2018 (Unaudited)	31.03.2019 (Audited)	31.03.2018 (Audited)
I	Revenue From Operations					
II	Other Income	1646.34	2145.75	1826.06	3971.81	4237.42
III	TOTAL REVENUE (I + II)	14.12	32.33	1.53	33.86	22.00
IV	EXPENSES:	1,660.46	2,178.08	1,827.59	4,005.67	4,259.42
	Cost of Material Consumed					
	Purchase of Stock-In-Trade	1469.62	1697.13	1949.35	3646.48	3755.44
	Change In Inventories	0.00	0.00	0.00	0.00	0.00
	Finance Cost	-7.80	286.95	-286.23	0.72	13.48
	Employee Benefit Expenses	13.41	6.32	4.39	10.71	34.07
	Depreciation and amortization	69.39	17.34	54.79	72.13	88.15
	Other Expenses	15.92	29.63	14.19	43.82	45.55
	TOTAL EXPENSES	79.31	113.79	70.53	184.32	273.93
V	PROFIT / (LOSS) FROM OPERATION BEFORE EXCEPTIONAL AND EXTRAORDINARY ITEMS AND TAX (III-IV)	1,639.85	2,151.16	1,807.02	3,958.18	4,210.63
VI	Exceptional Items	20.61	26.92	20.57	47.49	48.79
VII	PROFIT / (LOSS) BEFORE EXTRAORDINARY ITEMS AND TAX (V-VI)	0.00	0.00	0.00	0.00	0.00
VIII	Extraordinary items	20.61	26.92	20.57	47.49	48.79
IX	PROFIT / (LOSS) BEFORE TAX (VII-VIII)	0.00	0.00	0.00	0.00	0.00
X	TAX EXPENSE:	20.61	26.92	20.57	47.49	48.79
	(1) Current Tax					
	(2) Deferred Tax	0.00	11.75	0.00	11.75	13.08
	(3) MAT Credit	0.00	-5.35	0.00	-5.35	-2.90
		0.00	0.00	0.00	0.00	0.00
XI	NET PROFIT / (LOSS) FROM CONTINUING OPERATIONS (VII-VIII)	20.61	20.52	20.57	41.10	38.61
XII	NET PROFIT / (LOSS) FROM DISCONTINUING OPERATIONS	0.00	0.00	0.00	0.00	0.00
XIII	TAX EXPENSE OF DISCONTINUING OPERATIONS	0.00	0.00	0.00	0.00	0.00
XIV	NET PROFIT / (LOSS) FROM DISCONTINUING OPERATIONS (after Tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV	Profit/Loss for the period(XI+XIV)	20.61	20.52	20.57	41.10	38.61
XVI	NET PROFIT / (LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT / (LOSS) OF ASSOCIATES (13 + 14 + 15) *	20.61	20.52	20.57	41.10	38.61
XVII	Paid-up equity share capital (Face Value of the Share shall be indicated)	615.50	615.50	585.50	615.50	585.50
XVIII	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	600.96	508.86	508.86	508.86	63.89
XIX	Earnings Per Share (before extraordinary items) (of Rs ___/- each) (not annualised):					
	(1)BASIC	0.33	0.33	0.35	0.67	0.66
	(2)DILUTED	0.33	0.33	0.35	0.67	0.66
XX	Earnings Per Share (after extraordinary items) (of Rs ___/- each) (not annualised):					
	(1)BASIC	0.33	0.33	0.35	0.67	0.66
	(2)DILUTED	0.33	0.33	0.35	0.67	0.66
	* Applicable in the case of consolidated results.					

Notes:


- Figures for the six months ended March 31, 2019 are balancing figures between audited figures in respect of full financial year and the published year to date figures up to the first half of the relevant year.
- The figures upto the end of the first half were only reviewed and were not audited.

The above financial results of the company for the half year ended 30 September, 2019 have been reviewed by the audit committee and approved by the Board of directors at its meeting held on November 13, 2019.

4 Segment Reporting is not applicable, since the company is involved in one segment only

For and on behalf of Board of Ajooni Biotech Limited

Place : Mohali
Date : 13.11.2019


 Jasjit Singh
 Director
 DIN: 01937631★

AJOONI BIOTECH LIMITED

CIN : U85190PB2010PLCO40162

STATEMENT OF ASSETS AND LIABILITIES

UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES (Rs. IN LAKHS)

Particulars	AS ON 30.09.2019	AS ON 31.03.2019
	Unaudited	Audited
I. EQUITY AND LIABILITIES		
(1) SHAREHOLDER'S FUND		
(A) SHARE CAPITAL		
(B) RESERVES AND SURPLUS	615.50	615.50
(C) MONEY RECEIVED AGAINST SHARE WARRANTS	622.03	600.96
SUB-TOTAL - SHAREHOLDERS' FUNDS		
(2) SHARE APPLICATION MONEY PENDING ALLOTMENT	1,237.53	1,216.46
(3) MINORITY INTEREST *		
(4) NON CURRENT LIABILITIES		
(A) LONG TERM BORROWINGS		
(B) DEFERRED TAX LIABILITIES (NET)	30.43	16.01
(C) OTHER NON-CURRENT LIABILITIES	-	-
(D) LONG-TERM PROVISIONS	399.72	399.72
SUB-TOTAL - NON-CURRENT LIABILITIES		
(5) CURRENT LIABILITIES	430.15	415.73
(A) SHORT TERM BORROWINGS		
(B) TRADE PAYABLE	207.33	50.27
(C) OTHER CURRENT LIABILITIES	151.44	73.71
(D) SHORT TERM PROVISIONS	87.79	56.42
SUB-TOTAL - CURRENT LIABILITIES	0.62	12.39
TOTAL EQUITY & LIABILITIES	447.18	192.79
II. ASSETS	2,114.86	1,824.98
(1) NON CURRENT ASSETS		
(A) FIXED ASSETS		
(i) TANGIBLE ASSETS		
(B) GOODWILL ON CONSOLIDATION *	104.33	102.20
(C) NON CURRENT INVESTMENTS		
(D) DEFERRED TAX ASSETS (NET)	363.02	376.40
(E) LONG TERM LOANS & ADVANCES	9.29	9.29
(F) OTHER NON CURRENT ASSETS	111.72	111.72
SUB-TOTAL - NON-CURRENT ASSETS	42.21	42.21
(2) CURRENT ASSETS	630.57	641.82
(A) CURRENT INVESTMENTS		
(B) INVENTORIES		
(C) TRADE RECEIVABLES	506.00	506.89
(D) CASH AND CASH EQUIVALENTS	805.52	483.33
(E) SHORT TERM LOANS AND ADVANCES	29.85	73.07
(F) OTHER CURRENT ASSETS	142.91	119.86
SUB-TOTAL - CURRENT ASSETS	0.00	-
TOTAL-ASSETS	1484.29	1183.16
*APPLICABLE IN THE CASE OF CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES	2,114.86	1,824.98

For and on behalf of Board of Ajooni Biotech Limited

Place : Mohali

Date : 13.11.2019

Jasjot Singh

Director

DIN: 01937631